Aprocitentan (BioDeep_00000730206)
代谢物信息卡片
化学式: C16H14Br2N6O4S (543.9164)
中文名称: N-[5-(4-溴苯基)-6-[2-[(5-溴-2-嘧啶基)氧基]乙氧基]-4-嘧啶基]氨基磺酰胺
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: C1=CC(=CC=C1C2=C(N=CN=C2OCCOC3=NC=C(C=N3)Br)NS(=O)(=O)N)Br
InChI: InChI=1S/C16H14Br2N6O4S/c17-11-3-1-10(2-4-11)13-14(24-29(19,25)26)22-9-23-15(13)27-5-6-28-16-20-7-12(18)8-21-16/h1-4,7-9H,5-6H2,(H2,19,25,26)(H,22,23,24)
描述信息
C28313 - Endothelin Receptor Antagonist
Aprocitentan (ACT-132577) is the major and pharmacologically active metabolite of Macitentan. Aprocitentan is dual ETA/ETB antagonist with IC50s of 3.4 nM and 987 nM, and pA2 valus of 6.7 and 5.5, respectively[1].
同义名列表
2 个代谢物同义名
数据库引用编号
8 个数据库交叉引用编号
- ChEBI: CHEBI:76609
- KEGGdrug: D87138
- KEGGdrug: D11441
- PubChem: 25099191
- DrugBank: DB15059
- ChEMBL: CHEMBL2165326
- CAS: 1103522-45-7
- medchemexpress: HY-15895
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
| 亚细胞结构定位 | 关联基因列表 |
|---|
文献列表
- Magda S C Fontes, Jasper Dingemanse, Patricia N Sidharta. Multiple-Dose Pharmacokinetics, Safety, and Tolerability of Aprocitentan, a Dual Endothelin Receptor Antagonist, in Healthy Japanese and Caucasian Subjects.
Clinical pharmacology in drug development.
2021 07; 10(7):718-725. doi:
10.1002/cpdd.881. [PMID: 33063477] - Emily K McCoy, Katelin M Lisenby. Aprocitentan (a Dual Endothelin-Receptor Antagonist) for Treatment-Resistant Hypertension.
Journal of cardiovascular pharmacology.
2021 06; 77(6):699-706. doi:
10.1097/fjc.0000000000001023. [PMID: 34001723] - Pierre Gueneau de Mussy, Patricia N Sidharta, Gregoire Wuerzner, Marc P Maillard, Nicolas Guérard, Marc Iglarz, Bruno Flamion, Jasper Dingemanse, Michel Burnier. Effects of the Dual Endothelin Receptor Antagonist Aprocitentan on Body Weight and Fluid Homeostasis in Healthy Subjects on a High Sodium Diet.
Clinical pharmacology and therapeutics.
2021 03; 109(3):746-753. doi:
10.1002/cpt.2043. [PMID: 32897570] - Patricia N Sidharta, Hartmut Fischer, Jasper Dingemanse. Absorption, Distribution, Metabolism, and Excretion of Aprocitentan, a Dual Endothelin Receptor Antagonist, in Humans.
Current drug metabolism.
2021; 22(5):399-410. doi:
10.2174/1389200222666210204202815. [PMID: 33563190] - Patricia N Sidharta, Jasper Dingemanse. Effects of Multiple-Dose Administration of Aprocitentan on the Pharmacokinetics of Rosuvastatin.
Clinical pharmacology in drug development.
2020 11; 9(8):995-1002. doi:
10.1002/cpdd.815. [PMID: 32592633] - Patricia N Sidharta, Jasper Dingemanse. Effect of Multiple-Dose Aprocitentan Administration on the Pharmacokinetics of Midazolam in Healthy Male Subjects.
European journal of drug metabolism and pharmacokinetics.
2020 Apr; 45(2):227-234. doi:
10.1007/s13318-019-00590-8. [PMID: 31773427] - Pierre Verweij, Parisa Danaietash, Bruno Flamion, Joël Ménard, Marc Bellet. Randomized Dose-Response Study of the New Dual Endothelin Receptor Antagonist Aprocitentan in Hypertension.
Hypertension (Dallas, Tex. : 1979).
2020 04; 75(4):956-965. doi:
10.1161/hypertensionaha.119.14504. [PMID: 32063059] - Patricia N Sidharta, Ivan Ulč, Jasper Dingemanse. Single-Dose Pharmacokinetics and Tolerability of Aprocitentan, a Dual Endothelin Receptor Antagonist, in Subjects with Severe Renal Function Impairment.
Clinical drug investigation.
2019 Nov; 39(11):1117-1123. doi:
10.1007/s40261-019-00837-x. [PMID: 31435905] - Patricia N Sidharta, Meggane Melchior, Martin K Kankam, Jasper Dingemanse. Single- and multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the dual endothelin receptor antagonist aprocitentan in healthy adult and elderly subjects.
Drug design, development and therapy.
2019; 13(?):949-964. doi:
10.2147/dddt.s199051. [PMID: 30962677] - Milena Issac, Jasper Dingemanse, Patricia N Sidharta. Pharmacokinetics of Macitentan in Patients With Pulmonary Arterial Hypertension and Comparison With Healthy Subjects.
Journal of clinical pharmacology.
2017 08; 57(8):997-1004. doi:
10.1002/jcph.888. [PMID: 28378883] - Alexander Treiber, Päivi Äänismaa, Ruben de Kanter, Stephane Delahaye, Marianne Treher, Patrick Hess, Patricia Sidharta. Macitentan does not interfere with hepatic bile salt transport.
The Journal of pharmacology and experimental therapeutics.
2014 Jul; 350(1):130-43. doi:
10.1124/jpet.114.214106. [PMID: 24769543] - Jacob Atsmon, Jasper Dingemanse, Dimitri Shaikevich, Inna Volokhov, Patricia N Sidharta. Investigation of the effects of ketoconazole on the pharmacokinetics of macitentan, a novel dual endothelin receptor antagonist, in healthy subjects.
Clinical pharmacokinetics.
2013 Aug; 52(8):685-92. doi:
10.1007/s40262-013-0063-8. [PMID: 23568224] - Shirin Bruderer, Joanne Marjason, Patricia N Sidharta, Jasper Dingemanse. Pharmacokinetics of macitentan in caucasian and Japanese subjects: the influence of ethnicity and sex.
Pharmacology.
2013; 91(5-6):331-8. doi:
10.1159/000351704. [PMID: 23817130] - Shirin Bruderer, Päivi Aänismaa, Marie-Claude Homery, Stephanie Häusler, Kyle Landskroner, Patricia N Sidharta, Alexander Treiber, Jasper Dingemanse. Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist.
The AAPS journal.
2012 Mar; 14(1):68-78. doi:
10.1208/s12248-011-9316-3. [PMID: 22189899] - Marc Iglarz, Christoph Binkert, Keith Morrison, Walter Fischli, John Gatfield, Alexander Treiber, Thomas Weller, Martin H Bolli, Christoph Boss, Stephan Buchmann, Bruno Capeleto, Patrick Hess, Changbin Qiu, Martine Clozel. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist.
The Journal of pharmacology and experimental therapeutics.
2008 Dec; 327(3):736-45. doi:
10.1124/jpet.108.142976. [PMID: 18780830] - . .
.
. doi:
. [PMID: 22458347]
